STOCK TITAN

CytomX Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on March 1, 2022

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary

CytomX Therapeutics (CTMX) will report its fourth quarter and full year 2021 financial results on March 1, 2022, after U.S. market close. A conference call will follow at 5:00 p.m. ET to discuss results and provide updates. CytomX focuses on oncology therapeutics, notably through its Probody® technology. Its pipeline includes investigational drugs like praluzatamab ravtansine and CX-2029, both undergoing Phase 2 studies for advanced cancer types. Interested parties can access the conference call via the company’s website.

Positive
  • Company will disclose financial results on March 1, 2022, providing insights into its performance.
  • Pipeline includes advanced investigational drugs targeting difficult-to-treat cancers.
Negative
  • None.

SOUTH SAN FRANCISCO, Calif., Feb. 22, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that it will report fourth quarter and full year 2021 financial results on Tuesday, March 1, 2022, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 5:00 p.m. ET / 2:00 p.m. PT to discuss the results and provide a corporate update.

Participants may access the live webcast of the conference call from the Events and Presentations page of CytomX’s website at https://ir.cytomx.com/events-and-presentations. An archived replay of the webcast will be available on the Company’s website until March 8, 2022.

Audio Conference Call:

 U.S. Dial-in Number: (877) 809-6037
   
 International Dial-in Number:(615) 247-0221
   
 Conference ID: 8454049

About CytomX Therapeutics, Inc.
CytomX is a clinical-stage, oncology-focused biopharmaceutical company dedicated to destroying cancer differently. By pioneering a novel class of conditionally activated biologics, powered by its Probody® technology platform, CytomX’s goal is to transcend the limits of current cancer treatments by successfully leveraging therapeutic targets that were once thought to be inaccessible. CytomX’s robust and differentiated pipeline includes the wholly-owned praluzatamab ravtansine (CX-2009), an investigational conditionally activated antibody-drug conjugate (ADC) directed toward CD166, and CX-2029, an investigational conditionally activated ADC directed toward CD71 co-developed with AbbVie. These two programs are currently being evaluated in Phase 2 studies, targeting a variety of late-stage, difficult-to-treat cancer types, including breast cancer for praluzatamab ravtansine, and squamous non-small cell lung cancer, and head and neck squamous cell carcinoma for CX-2029. CytomX’s clinical pipeline also includes cancer immunotherapeutic candidates against validated targets such as the CTLA-4-targeting Probody therapeutics, BMS-986249 and BMS-986288, partnered with Bristol Myers Squibb, and our wholly-owned conditionally activated anti-PD-L1 antibody, pacmilimab (CX-072), as well as CX-904, a conditionally activated T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor on tumor cells and the CD3 receptor on T cells. CX-904 is entering Phase 1 clinical evaluation and is partnered with Amgen. In addition, CytomX has a diverse preclinical portfolio and strategic collaborations with multiple leaders in oncology, including AbbVie, Amgen, Astellas, and Bristol Myers Squibb. For more information about CytomX and how it is working to make conditionally activated treatments the new standard-of-care in the fight against cancer, visit www.cytomx.com and follow us on LinkedIn and Twitter.

Probody is a U.S. registered trademark of CytomX Therapeutics, Inc.

Investor Contact:
Chau Cheng, PhD MBA
VP, Investor Relations & Corp. Communications
ccheng@cytomx.com
Direct: (650) 273-4999

Media Contact:
Bret Coons
Director, Corporate Communications
bcoons@cytomx.com
Direct: (650) 528 2929


FAQ

When will CytomX report its financial results?

CytomX will report its fourth quarter and full year 2021 financial results on March 1, 2022, after market close.

What time is the CytomX conference call scheduled?

The conference call is scheduled for 5:00 p.m. ET on March 1, 2022.

What is the focus of CytomX Therapeutics?

CytomX specializes in conditionally activated oncology therapeutics, utilizing its Probody technology.

What investigational drugs are in CytomX's pipeline?

CytomX's pipeline includes praluzatamab ravtansine (CX-2009) and CX-2029, both in Phase 2 studies.

CytomX Therapeutics, Inc.

NASDAQ:CTMX

CTMX Rankings

CTMX Latest News

CTMX Stock Data

68.18M
77.39M
1%
65.67%
7.08%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SOUTH SAN FRANCISCO